S&P 500   3,847.28 (-0.12%)
DOW   31,155.10 (-0.11%)
QQQ   324.39 (+0.19%)
AAPL   134.62 (+1.96%)
MSFT   222.91 (-0.64%)
FB   269.50 (+0.76%)
GOOGL   1,913.61 (+1.78%)
AMZN   3,328.79 (+2.00%)
TSLA   846.56 (-0.46%)
NVDA   531.23 (-0.64%)
BABA   259.73 (-2.17%)
CGC   33.24 (-1.16%)
GE   11.29 (-0.88%)
MU   83.01 (-0.59%)
AMD   88.97 (+0.25%)
NIO   56.02 (-2.93%)
T   28.83 (-0.45%)
F   11.28 (+3.87%)
ACB   11.24 (-2.60%)
BA   210.00 (-0.69%)
DIS   171.86 (-1.03%)
NFLX   586.01 (-0.06%)
GILD   67.42 (-0.84%)
S&P 500   3,847.28 (-0.12%)
DOW   31,155.10 (-0.11%)
QQQ   324.39 (+0.19%)
AAPL   134.62 (+1.96%)
MSFT   222.91 (-0.64%)
FB   269.50 (+0.76%)
GOOGL   1,913.61 (+1.78%)
AMZN   3,328.79 (+2.00%)
TSLA   846.56 (-0.46%)
NVDA   531.23 (-0.64%)
BABA   259.73 (-2.17%)
CGC   33.24 (-1.16%)
GE   11.29 (-0.88%)
MU   83.01 (-0.59%)
AMD   88.97 (+0.25%)
NIO   56.02 (-2.93%)
T   28.83 (-0.45%)
F   11.28 (+3.87%)
ACB   11.24 (-2.60%)
BA   210.00 (-0.69%)
DIS   171.86 (-1.03%)
NFLX   586.01 (-0.06%)
GILD   67.42 (-0.84%)
S&P 500   3,847.28 (-0.12%)
DOW   31,155.10 (-0.11%)
QQQ   324.39 (+0.19%)
AAPL   134.62 (+1.96%)
MSFT   222.91 (-0.64%)
FB   269.50 (+0.76%)
GOOGL   1,913.61 (+1.78%)
AMZN   3,328.79 (+2.00%)
TSLA   846.56 (-0.46%)
NVDA   531.23 (-0.64%)
BABA   259.73 (-2.17%)
CGC   33.24 (-1.16%)
GE   11.29 (-0.88%)
MU   83.01 (-0.59%)
AMD   88.97 (+0.25%)
NIO   56.02 (-2.93%)
T   28.83 (-0.45%)
F   11.28 (+3.87%)
ACB   11.24 (-2.60%)
BA   210.00 (-0.69%)
DIS   171.86 (-1.03%)
NFLX   586.01 (-0.06%)
GILD   67.42 (-0.84%)
S&P 500   3,847.28 (-0.12%)
DOW   31,155.10 (-0.11%)
QQQ   324.39 (+0.19%)
AAPL   134.62 (+1.96%)
MSFT   222.91 (-0.64%)
FB   269.50 (+0.76%)
GOOGL   1,913.61 (+1.78%)
AMZN   3,328.79 (+2.00%)
TSLA   846.56 (-0.46%)
NVDA   531.23 (-0.64%)
BABA   259.73 (-2.17%)
CGC   33.24 (-1.16%)
GE   11.29 (-0.88%)
MU   83.01 (-0.59%)
AMD   88.97 (+0.25%)
NIO   56.02 (-2.93%)
T   28.83 (-0.45%)
F   11.28 (+3.87%)
ACB   11.24 (-2.60%)
BA   210.00 (-0.69%)
DIS   171.86 (-1.03%)
NFLX   586.01 (-0.06%)
GILD   67.42 (-0.84%)
Log in
NASDAQ:COLL

Collegium Pharmaceutical Stock Forecast, Price & News

$22.67
-0.41 (-1.78 %)
(As of 01/21/2021 09:45 AM ET)
Add
Compare
Today's Range
$22.67
Now: $22.67
$23.11
50-Day Range
$18.38
MA: $20.18
$24.06
52-Week Range
$13.00
Now: $22.67
$25.59
Volume760 shs
Average Volume436,716 shs
Market Capitalization$783.97 million
P/E Ratio46.27
Dividend YieldN/A
Beta1.27
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical logo

MarketRank

Overall MarketRank

1.79 out of 5 stars

Medical Sector

146th out of 1,928 stocks

Pharmaceutical Preparations Industry

70th out of 774 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:COLL
CUSIPN/A
Phone781-713-3699
Employees255

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$296.70 million
Book Value$2.61 per share

Profitability

Net Income$-22,720,000.00

Miscellaneous

Market Cap$783.97 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$22.67
-0.41 (-1.78 %)
(As of 01/21/2021 09:45 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

How has Collegium Pharmaceutical's stock price been impacted by COVID-19 (Coronavirus)?

Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, COLL shares have increased by 29.0% and is now trading at $22.67.
View which stocks have been most impacted by COVID-19
.

Is Collegium Pharmaceutical a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Collegium Pharmaceutical stock.
View analyst ratings for Collegium Pharmaceutical
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Collegium Pharmaceutical?

Wall Street analysts have given Collegium Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Collegium Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Collegium Pharmaceutical's CEO?

1,428 employees have rated Collegium Pharmaceutical CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Collegium Pharmaceutical's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Collegium Pharmaceutical
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its quarterly earnings results on Thursday, November, 5th. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.90 by $0.58. The specialty pharmaceutical company earned $77.40 million during the quarter, compared to analysts' expectations of $77.39 million. Collegium Pharmaceutical had a net margin of 5.71% and a return on equity of 12.64%. The company's revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.18) earnings per share.
View Collegium Pharmaceutical's earnings history
.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, January, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $330-350 million, compared to the consensus revenue estimate of $342.74 million.

What price target have analysts set for COLL?

8 equities research analysts have issued twelve-month target prices for Collegium Pharmaceutical's stock. Their forecasts range from $8.00 to $43.00. On average, they expect Collegium Pharmaceutical's stock price to reach $30.50 in the next year. This suggests a possible upside of 34.5% from the stock's current price.
View analysts' price targets for Collegium Pharmaceutical
or view Wall Street analyst' top-rated stocks.

Who are some of Collegium Pharmaceutical's key competitors?

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), (CGC), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the following people:
  • Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 56, Pay $104.34k)
  • Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 49, Pay $1.03M)
  • Mr. Paul J. Brannelly, Exec. VP & CFO (Age 47, Pay $644.89k)
  • Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 45, Pay $544.48k)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 36, Pay $594.26k)
  • Dr. Richard Malamut, Exec. VP & Chief Medical Officer (Age 60, Pay $618.69k)
  • Ms. Alex Dasalla, Head of Investor Relations
  • Mr. Bart J. Dunn, Exec. VP of Strategy & Corp. Devel.
  • Mr. Scott Dreyer, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Jack Maroney, VP of Sales

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include OneAscent Financial Services LLC (0.06%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends for Collegium Pharmaceutical
.

Which institutional investors are buying Collegium Pharmaceutical stock?

COLL stock was acquired by a variety of institutional investors in the last quarter, including OneAscent Financial Services LLC.
View insider buying and selling activity for Collegium Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $22.67.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $783.97 million and generates $296.70 million in revenue each year. The specialty pharmaceutical company earns $-22,720,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Collegium Pharmaceutical employs 255 workers across the globe.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.